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ABSTRACT
Cellular senescence is defined as an irreversible growth arrest with the acquisition 
of a distinctive secretome. The growth arrest is a potent anticancer mechanism 
whereas the secretome facilitates wound healing, tissue repair, and development. 
The senescence response has also become increasingly recognized as an important 
contributor to aging and age-related diseases, including cancer. Although oncogenic 
mutations are capable of inducing a beneficial senescence response that prevents 
the growth of premalignant cells and promotes cancer immune-surveillance, the 
secretome of senescent cells also includes factors with pro-tumorigenic properties. 
On June 23rd and 24th, 2016, the Division of Cancer Biology of the National Cancer 
Institute sponsored a workshop to discuss the complex role of cellular senescence 
in tumorigenesis with the goal to define the major challenges and opportunities 
within this important field of cancer research. Additionally, it was noted how the 
development of novel tools and technologies are required to accelerate research into 
a mechanistic understanding of senescent cells in carcinogenesis in order to overcome 
the current limitations in this exciting, yet ill-defined area.
INTRODUCTION
Cellular senescence is traditionally viewed as 
an autonomous, tumor-suppressive mechanism that 
irreversibly blocks cellular proliferation in response to a 
variety of stresses such as DNA damage, telomere attrition 
or oncogene activation [1, 2]. While significant attention 
is given to further elucidate the biological benefits of 
senescence, the understanding of its detrimental effects 
is also evolving, along with non-stress related functions. 
Senescent cells have been shown to promote neoplastic 
transformation and their elimination is found to delay 
tumor formation [1, 3]. Furthermore, senescent cells 
are genomically unstable and cancer therapy-induced 
senescence is associated with invasive and metastatic 
phenotypes in certain cancer types [1, 4]. Developmental 
forms of cellular senescence have been identified, which 
do not seem to be stress-induced and function in normal 
tissue growth and remodeling programs [5, 6].
Some of the key challenges to the narrowly 
structured, cell autonomous model of cellular senescence 
is that its induction in response to stress or developmental 
cues is not mediated by senescence-specific events, but 
rather represents a collection of cellular functions that 
may or may not occur in concert [1, 2]. Senescence, 
for instance, involves cell cycle arrest, DNA damage 
responses, epigenetic and nuclear envelope changes, 
along with autophagy and metabolic reprogramming 
that are often associated with other cellular events [1, 
2]. Nevertheless, these cellular programs are either 
directly or indirectly involved in driving a complex and 
highly plastic senescence-associated secretory phenotype 
(SASP) response [1, 4]. The SASP is comprised of 
numerous chemokines, growth factors, cytokines, 
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matrix metalloproteinases and small molecular weight 
metabolites [4]. From an aging perspective, senescent 
cells are known to accumulate over time, and increased 
numbers of senesced cells (and their SASP) are suspected 
to contribute to late-life deterioration of tissues and organs 
and drive age-related diseases, including cancer [1, 2]. 
It is currently unclear how dynamic the SASP is over 
time/age and how it may differ in response to different 
oncogenic or developmental signals. Furthermore, the 
composition of the SASP likely varies depending on 
the cell type undergoing senescence in different tissues. 
It is also unclear whether the SASP has beneficial and/
or deleterious contributions to tissue homeostasis and/
or cancer progression, as it may be extremely context 
dependent [7]. Paradoxically, senescence is seemingly 
preferred to apoptosis in response to oncogenic stimuli, 
and the genetic background of cells subjected to stress 
conditions may preferentially trigger senescent and/or 
apoptotic pathways, but the evolutionary advantage for 
this predilection remains poorly understood [8].
In light of its multi-dimensional functions, 
alternative regulatory pathways and context-specific 
effects, it is becoming increasingly clear that there may 
be multiple classes of senescent cells, ranging from acute 
(programmed) senescent cells to chronic (spontaneous 
age-related) and disease-related senescent cells, along 
with various forms of tumor-related senescent cells such 
as senescent cancer cells, senescent stromal cells, therapy-
induced senescent cells, and bystander senescent cells 
[9]. Each of these may consist of several senescent cell 
subclasses that may be in different stages of induction 
(early versus late/deep senescence), illustrating the 
immense complexity of the problem of establishing how 
senescence contributes to cancer or other age-related 
disorders.
As the field of senescence biology matures, so is 
the awareness of its inherent complexities and potentially 
harmful effects. From a cancer biology standpoint, 
important questions about the senescence-associated 
benefits and detriments have emerged – including 
questions about its significance (and involvement) in 
tumor initiation, its contribution to tumor heterogeneity 
and resistance to therapy, and the extent to which senescent 
cells are necessary for normal organ function/homeostasis 
or whether they persist and remain irreversibly cell cycle 
arrested in aging host tissues. These salient questions 
are accompanied by the realization that critical tools are 
missing, for instance, to fate map these cells in vivo, or to 
catalog their unique SASP over time or eliminate them in 
a spatiotemporal manner.
To assess the impact of senescent cells on cancer, the 
Division of Cancer Biology (DCB) at the National Cancer 
Institute (NCI) organized a workshop in explore the role 
of the senescent cells to tumor initiation and promotion. 
A panel of experts, chaired by Judy Campisi (Buck 
Institute) and Jan van Deursen (Mayo Clinic), summarized 
the current state of the field (including its limitations) 
and highlighted promising research directions and 
opportunities that could enhance our understanding of how 
senescent cells both suppress and contribute to cancer. The 
meeting summary highlights research priorities and aims 
to stimulate basic and translational research to generate 
a better understanding of the molecular mechanisms 
regulating oncogenic senescence, with the ultimate goal 
to leverage insights gained for improved cancer therapies.
SENESCENCE AS A MULTIFACETED 
PROGRAM
Cellular senescence likely evolved as a tumor 
suppressive program by which damaged cells irreversibly 
arrest proliferation to halt progression to malignancy. 
Now, however, senescence is emerging as a more complex 
physiological phenomenon observed at all stages of life 
and with far reaching consequences. Senescent cells have 
now been observed in several diverse biological processes, 
including embryogenesis [5, 6], tissue remodeling, wound 
healing [7, 10] and chromatin reorganization [11]. In this 
session, the detrimental and beneficial roles of senescence 
and the SASP were discussed. 
Bill Keyes (Center for Genomic Regulation; 
Barcelona, Spain) discussed the complex effects of the 
SASP on cellular plasticity, tissue regeneration, and tumor 
growth. Recent developments in the Keyes Laboratory 
show that induction of oncogene-induced senescence 
paradoxically coincides with increased expression of tissue 
specific stem cell markers in primary mouse keratinocytes. 
Extending this to an in vivo model of senescence, the 
DMBA/TPA-induced skin carcinogenesis model further 
supported that senescent cells express increased stem 
cell markers, including CD34, a marker of hair follicle 
bulge stem cells. These cells not only are required for 
hair follicle regeneration, but also represent the cell 
of origin in papilloma and squamous cell carcinomas 
(SCCs). To further explore the link between senescence 
and stemness, Ras-induced keratinocytes undergoing 
senescence were transplanted into full thickness wounds 
in nude mice. Remarkably, this transplant model also 
resulted in papilloma formation, which were identical to 
DMBA/TPA induced lesions, including an aberrant layer 
of CD34+ cells. However, tracing of the transplanted 
senescing cells revealed that not all of the papilloma arose 
from the grafted cells, and included regions recruited from 
the endogenous keratinocytes. This suggests that the SASP 
may play a role in directing papilloma development. 
In support of this observation, they next identified 
that transient (2 days) exposure of normal mouse 
primary epidermal keratinocytes to conditioned media 
(CM) from oncogene-induced senescent cells also 
results in an increase in CD34+ cells. Accordingly, the 
transiently conditioned keratinocytes were capable of 
re-epithelializing full-thickness wounds upon in vivo 
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transplantation onto the dorsal surface of athymic nude 
mice and of regenerating fully functional hair follicles. 
This suggests that components of the SASP can induce 
stem cell functionality and regenerative capacity. 
Curiously however, these cells also expressed increased 
senescence-associated β-galactosidase (SAβG), but not 
p16Ink4a. In stark contrast, chronic CM/SASP exposure (7 
days), while increasing stem cell marker gene expression 
further, now caused a cell-intrinsic paracrine arrest of the 
cultured normal primary cells. This suggests that the SASP 
can induce beneficial plasticity, but when prolonged, one 
which is blocked by a cell-intrinsic senescence arrest.
Collectively these results suggest that non-cell 
autonomous effects of the SASP can induce cell plasticity 
by initially driving keratinocyte dedifferentiation, but 
when prolonged, this is sensed as aberrant or tumor-
promoting, and is counteracted by a cell-intrinsic 
senescence arrest. This SASP-induced plasticity appears to 
be essential during tissue regeneration/wound healing but 
also repurposed (and usurped) during papillomagenesis. 
The extent to which regeneration- and tumorigenesis-
based senescence are similar and/or distinct remains to be 
determined.
The discussion on SASP-induced cellular plasticity 
was continued by Manuel Serrano (Spanish National 
Cancer Center (CNIO); Madrid, Spain). He first argued 
that cell culture and in vivo cellular processes (including 
senescence) likely have more similarities than differences 
– and that true tissue culture artifacts are unlikely to be as 
pervasive as many believe them to be. He then introduced 
his work on how senescence contributes to in vivo cell 
plasticity and repair programs in an evolutionarily 
advantageous manner by inducing a pro-inflammatory 
response, unlike apoptosis. Cellular reprogramming has 
been well established and characterized in vitro using the 
Yamanaka transcription factors, which includes Oct4, 
Sox2, Klf4, and c-Myc [12]. To test the consequences of 
cellular reprogramming in vivo, the Serrano laboratory 
developed a tetracycline-inducible mouse (i4F) to 
ubiquitously express the four Yamanaka transcription 
factors (13). Treatment of adult mice with doxocycline 
for 1-3 weeks results in widespread dysplasia, along 
with loss of cell identity (in a process defined as “de-
differentiation”), and detection of circulating induced 
pluripotent stem cells (iPSCs) in the blood. Furthermore, 
elevated levels of Nanog (a marker of undifferentiated 
stem cells) were noted, along with SAβG activity and 
increased p21Cip1 in the liver, kidney, stomach, pancreas 
and intestine – albeit Nanog and senescence markers 
are not expressed in the same cells. Curiously, this i4F-
mediated effect is not observed in the lung, unless first 
exposed to the DNA damaging agent, bleomycin. After 
~4 weeks of constant doxycycline exposure, the mice die 
of intestinal hyperplasia. Nevertheless, if doxycycline 
is removed, full recovery is achieved after two weeks. 
However, ~2 months out from doxycycline cessation, a 
few reprogrammed cells continue to grow and ultimately 
develop into teratomas and other types of cancer. [13]. It 
has been shown that p53 and p16Ink4a are barriers to cellular 
reprogramming in vitro. To determine the relationship 
between cellular reprogramming and senescence in 
vivo, i4F mice were created that lack either one of these 
important regulators. Deletion of p53 promotes higher rates 
of reprogramming, teratoma formation, and paradoxically 
senescence. Interestingly, reprogrammed cells (i.e., 
positive for Nanog) are located in close proximity to 
senescent cells (ie., positive for SAβG or p21Cip1), but 
there is no indication that these cells exhibit any senescent 
cell characteristics. Loss of p16Ink4a/p19Arf on the other 
hand limits reprogramming and senescence in i4F mice, 
which leads to fewer teratomas. These results suggest that 
p16Ink4a is required for in vivo reprogramming-induced 
senescence. Furthermore, inflammation and the SASP are 
essential components of this process, as treatment with 
IKK and PIM-1 inhibitors or αIL6 antibodies reduce the 
reprogramming efficiency, as does treatment with ABT-
263 (Navitoclax, a first generation senolytic). Conversely, 
treatment with palbociclib, a selective CDK4/6 inhibitor 
that promotes senescence, has the opposite effect. As the 
i4F mice do not express the reprogramming factors in 
the lungs, the animals were first treated with bleomycin 
to induce senescence, followed by the administration of 
doxycycline. Only bleomycin-treated lungs (which harbor 
senescent cells) undergo reprogramming.To substantiate 
this finding, they also observed that older mice reprogram 
more efficiently than younger mice because old mice 
harbor a senescence-rich microenvironment, which 
highlights the importance of senescence in this process. 
In keeping with his introduction, Dr. Serrano concluded 
by pointing out that leukemia inhibitory factor (LIF) 
is a critical (but often overlooked) factor for cellular 
reprogramming. While it is not one of the Yamanaka 
factors, LIF is related to IL6, suggesting that IL6 may be 
required for efficient reprogramming in both cultured cells 
and in vivo platforms. 
Ana Banito (Memorial Sloan Kettering Cancer 
Center; New York, USA) concluded this session by 
focusing on how senescent cells remodel the enhancer 
landscape to control the SASP [11]. Using oncogene-
induced senescent IMR90 (human fetal lung) fibroblasts, 
they found that, unlike quiescence, RasG12D-induced 
senescence results in appreciable changes in the typical 
enhancer and super enhancer profiles as determined 
through H3K27Ac ChIP-seq analysis. Of the >32,000 
H3K27Ac-marked enhancers identified, 1,255 are super 
enhancers. Of these, a subset of 191 are inactivated, 
including many in proximity to proliferation genes such as 
E2F target genes. Furthermore, they found that 198 super 
enhancers are activated in senescence, many of which are 
near SASP genes, including IL8 and IL1α. Moreover, the 
chromatin reader BRD4 was identified as a regulator of the 
SASP and its downstream paracrine signaling. In senescent 
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cells, BRD4 is highly enriched at super enhancers near 
SASP genes, including IL1α, IL1β, IL8, MMP-1 and 
MMP-10, suggesting that BRD4 is an important regulator 
of the inflammatory features of the SASP. Furthermore, in 
vivo BRD4 ablation (via shRNA) or inhibition (via BET 
inhibitors) markedly decreases the SASP and inhibits the 
cytotoxicity of natural killer (NK) cells without affecting 
other features of the senescent phenotype such as cell 
growth arrest. In line with its role as a regulator of the 
SASP, BRD4 was also found to be essential in maintaining 
tumor suppressive immune surveillance [11]. This study 
underscores the importance of BRD4 in controlling the 
SASP and its ability to mediate senescent cell clearance. 
It also highlights the fact that not all SASP is detrimental, 
but it is unclear what SASP components are beneficial and 
which ones are detrimental, and to what extent restoring 
the beneficial ones to tumor cells could prove useful in re-
triggering the immune surveillance program.
SENESCENCE IN AGING AND CANCER
Cellular senescence has long been acknowledged as 
a potent anti-cancer mechanism that establishes a stable 
and irreversible cell cycle arrest of precancerous cells 
[14]. While these intrinsic tumor suppressive properties 
are clearly advantageous, recent evidence suggests 
that senescent cells are not genomically stable, and the 
mere presence of senescent cells and their SASP can act 
extrinsically to promote neoplastic transformation of 
premalignant cells [15, 16]. This double-edged sword 
of tumor protection and promotion is beginning to be 
understood and it has become imperative to determine how 
to keep the benefits of senescence intact while avoiding the 
deleterious consequences. A limitation to understanding 
the mechanistic underpinnings of senescence and the 
SASP is that many studies have been performed in 
tissue culture where a large number of relatively uniform 
senescent cells can be used for analyses. Identification and 
characterization of senescent cells in tissues is complicated 
by the fact that a single, distinguishing, unique factor of 
senescence has not been established. Identifying novel 
biomarkers and means of isolating and characterizing this 
rare cell type from aged and diseased tissues will greatly 
enhance our understanding of how these cells promote 
dysfunction.
John Sedivy (Brown University; Providence, 
USA) discussed the epigenetic alterations that occur in 
senescent cells. He highlighted his recent publication that 
used replicatively senescent human diploid fibroblasts 
(HDFs) for whole-genome chromosome conformation 
(Hi-C) assessments in combination with fluorescence 
in situ hybridization (FISH) painting to establish the 
three-dimensional chromatin architectural alterations 
and to map the chromosomal territorial shifts that 
occur in senescence [17]. They found that while there 
is generalized compaction and shrinkage of chromatin, 
senescent cells tend to gain close range interactions and 
lose long-range interactions. This compaction pattern 
coincides with a reduction in total volume occupied by 
chromosome arms. Interestingly, the highly repetitive (and 
retrotransposable elements-rich) regions of centromeres 
and peri-centromeres become enlarged and distended in 
senescent cells. Using formaldehyde assisted isolation of 
regulatory elements (FAIRE), the Sedivy team shows that 
chromatin profiles of senescent cells exhibit a generalized 
loss in signal at normally open, nucleosome-poor 
enhancers and promoters of active genes, while gaining 
signal in gene-poor heterochromatic regions [18]. The 
consequence of this is that transcription and translation of 
highly repetitive satellites and retrotransposons increases 
in senescent cells, which is in accordance with an increase 
in centromeric and peri-centromeric volume in senescent 
cells. Further tests also indicate that transposition in 
senescent cells requires three distinct alterations, including 
loss of RB, loss of TREX1 endonuclease and a gain of 
FOXA1, which collectively drive Line-1 transcription, 
transposition and associated DNA damage and senescence. 
Interestingly, if these factors are restored to normal in 
senescent cells, transposition is stopped. Dr. Sedivy then 
redirected the discussion to how Polycomb Group (PcG) 
chromatin regulators might influence epigenetic alterations 
in senescent cells. Based on recent developments in his 
lab, he proposed a “WNT-MYC-EZH2 axis” model, where 
loss of members from this pathway promotes senescence. 
Enhancer of Zeste Homolog 2 (EZH2), a PcG histone 
methyltransferase of H3K27, is reduced in senescent cells, 
which leads to an induction of the INK4A-ARF locus [19]. 
Dr. Sedivy’s group has found that the downregulation of 
EZH2 promotes cellular senescence through a bimodal 
and complementary set of mechanisms. On the one hand, 
loss of EZH2 downstream of reduced WNT-MYC axis 
signaling leads to H3K27me3-independent activation 
of a rapid and robust ATM/p53/p21Cip1-dependent 
DNA damage response and S-phase checkpoint. This 
is likely due to DNA damage that incurs from DNA 
replication fork collapse in the absence of functional 
Polycomb complexes. On the other hand, loss of EZH2 
methyltransferase activity will cause a gradual loss of 
H3K27me3, which in turn results in the de-repression 
and induction of p16Ink4a and SAβG activation, along with 
mTOR/NFκB-mediated production of the SASP. He closed 
with a “S-phase vulnerability” hypothesis requirement for 
entry into senescence, where mitotically competent cells 
experiencing prolonged/unresolvable stresses accumulate 
DNA damage and enter a permanent state of cell cycle 
arrest. 
Sheila Stewart (Washington University School 
of Medicine; St. Louis, USA) began by acknowledging 
that cancer predisposition is inherently linked to aging, 
however the mechanisms underlying this link are 
relatively unknown. Intrinsic changes in mutational 
load and stochastic senescence of cells increases 
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dramatically with age, suggesting that they may facilitate 
the development of late-life cancer and associated 
metastasis. Using the FASST mouse (Fibroblasts 
Accelerate Stromal-Supported Tumorigenesis) model 
with an inducible LSL-p27Kip1 cassette knocked into the 
ROSA26 locus, they are able to induce p27Kip1-driven 
senescence specifically in osteoblasts once these mice are 
crossed to a pro-alpha 2(I) collagen promoter-driven Cre-
ER transgenic. Intracardial injection of isogenic NT2.5 
murine breast cancer cells into this FASST mouse results 
in increased osteoclastogenesis and bone metastases that 
correlates with enrichment for p27Kip1-induced osteoblast 
senescence (i.e., SAβG+) and SASP expression (i.e., 
IL6+, among others) [20]. Conversely, neutralization of 
IL6 as a key SASP factor is sufficient to limit the effects 
of osteoblast senescence and SASP in attracting breast 
cancer cells to the bone and consequently reducing the 
tumor burden [20]. Additionally, Dr. Stewart presented 
data on how senescent stromal cells may impact primary 
tumor growth. Here the focus was on skin and senescent 
dermal fibroblasts [21]. While it is known that senescent 
fibroblasts accumulate with age in mouse and human skin 
alike, data from the Stewart lab points to the concomitant 
clustering and co-localization of CD45+ immune cells 
near the FASST-induced senescent fibroblasts and in the 
aged murine and human skin. Further analysis revealed 
that cells known to suppress the adaptive immune system 
– such as immature granulocytes and regulatory T cells 
– are increased in senescent/aging stroma. Interestingly, 
treatment of bone marrow cells with either FASST mouse-
derived senescent or non-senescent fibroblast CM resulted 
in a significant expansion of immature granulocytes in the 
group cultured with senescent fibroblast CM. Furthermore, 
senescent fibroblast and CM-educated granulocytes are 
able to suppress CD8+ cells in co-culture assays, unlike 
the non-senescence CM-educated cells. These effects are 
recapitulated in vivo, where tumor growth of isogenic 
murine SCC lines (PDSC5 and MK16-Ras) only occurs 
when they are co-injected sub-cutaneously onto FVB 
mice with senesced murine dermal fibroblasts – yet are 
readily blocked upon depletion of IL6 and/or immature 
granulocytes via αIL6 (or fibroblast-specific shRNA) and/
or αLy6G neutralizing antibody treatment. This protective 
effect is reversed if αCD8 antibodies are administered, 
and establishes a link between stromal senescence, SASP-
mediated immune suppression and cancer [21]. Together, 
these results suggest that changes in the distal or primary 
site microenvironment due to components secreted from 
senescent cells promote a permissive and metastatic niche 
that facilitates tumor growth and cell engraftment.
In the final talk of this session, Jan Vijg (Albert 
Einstein College of Medicine; New York, USA) discussed 
the challenges faced in the field to accurately measure 
genome instability during aging and in senescence at the 
single cell level. In collaboration with Cristina Montagna’s 
group, Dr. Vijg’s team developed a combination of assays 
to accurately detect single nucleotide variations (SNV) 
and genome structural variations (SV) in individual cells 
– events that may otherwise be diluted/subtracted out 
when analyzed in aggregate approaches. Published FISH 
and fluorescence-activated cell sorting (FACS) analysis 
of cerebral cortex-derived cells show that aneuploidy is 
not uncommon, increases with age (as demonstrated for 
mouse chromosomes 7, 18 and Y) and is concentrated 
in replication competent glial cells as opposed to non-
dividing neurons [22]. Follow up studies using the novel 
SNV/SV technologies on a variety of human (IMR90 
and BJ fibroblasts, B- and T-cells) and murine (mouse 
embryonic fibroblasts) cell types support the notion that, 
at the single cell level, the mutational load (involving 
chromosome gains/losses, point mutations, and genome 
structural variations) increases with senescence and aging. 
This also confirms what has been observe and documented 
by others [23], but at a much more informative scale that 
enables the linkage of specific mutation events on a per 
cell basis to senescence and aging as biological endpoints. 
Together these results suggest that careful analysis of 
individual senescent cells for genomic instability are 
technically possible and may illuminate how senescence 
and genome instability are linked.
DETRIMENTAL EFFECTS OF THERAPY-
INDUCED SENESCENCE
Chemotherapeutic strategies designed to kill a high 
percentage of cancer cells are increasingly being shown 
to induce cellular senescence in vivo in a variety of cells, 
both cancerous and non-cancerous [4]. Over time, these 
therapy-induced senescent cells evade clearance by the 
immune system and accumulate in the body, where they 
have the potential of producing a SASP [24]. Ironically, 
this SASP-enriched condition may in fact create a 
microenvironment within tissues that favors cancer 
growth [4, 24]. Equally as significant, there is growing 
appreciation for how genetic polymorphisms in differing 
populations may dictate cellular effects/outcomes to 
standard anti-cancer therapeutics. 
Maureen Murphy (The Wistar Institute; 
Philadelphia, USA) discussed the functional significance 
of a single nucleotide polymorphism of the tumor 
suppressor p53 that is found in a subset of African 
Americans [25]. Typically, codon 47 of p53 encodes for 
the amino acid proline (P), but they found a polymorphism 
that alters this proline (P47) to a serine (S47). The S47 
variant impairs the phosphorylation status of S46 that 
is mediated by proline-dependent kinases, including 
p38MAPK, HIPK2 and DYRK [25]. To understand the 
functional significance of the S47 variant in vivo, they 
utilized the humanized p53 knock-in (Hupki) p53 allele to 
develop a S47-specific knock-in mouse. Wild-type (WT) 
human or mouse p53 triggers potent cell death in response 
to genotoxic agents including etoposide, doxorubicin, and 
Oncotarget27666www.impactjournals.com/oncotarget
γ-irradiation (IR). Interestingly, S47 cells (exemplified by 
Hupki mouse embryonic fibroblasts and human-derived 
and EBV-immortalized polymorphic lymphoblast cell 
lines) show only a modest reduction in cell death upon 
exposure to these stresses. Surprisingly, there are no 
marked differences in growth arrest or transactivation of 
most p53 target genes between p53 wild-type and S47 
cells [25]. However, the S47 variant appears to have 
increased reactive oxygen species (ROS) and  senescence, 
which is accompanied by OXPHOS → Glycolytic 
metabolic shift (i.e., Warburg Effect) and extreme 
resistance to cisplatin-induced cell death. Mechanistically, 
cisplatin induces cell death in part by ferroptosis, an iron 
mediated non-apoptotic cell death that is driven by p53. 
Resistance of the S47 variant to ferroptosis was attributed 
to its impaired ability to transactivate a subset of p53 
target genes involved in metabolism and ferroptosis, 
GLS2 (glutaminase 2), and SCO2 (cytochrome c oxidase 
assembly protein). In line with the S47 variant’s defect 
in the tumor suppressive function of ferroptosis, both 
homozygous and heterozygous S47 mice are more prone 
to various types of cancer (and metastasis), including 
pancreatic cancer, colorectal cancer, hepatocellular 
carcinoma and the extremely rare histiocytic sarcoma 
[25]. Taken together, this work identified a functional role 
for the S47 variant in vivo, which may, in part, underlie 
the increased susceptibility of African Americans to 
carcinogenesis and contribute to its disparities-linked 
aggressiveness and resistance to therapy. 
Igor Roninson (University of South Carolina; 
Columbia, USA) discussed the importance of modulating 
chemotherapy-induced senescence and SASP-related 
paracrine effects that may interfere with treatment efficacy. 
He argues that the secretory phenotype associated with 
DNA damaging agents like doxorubicin results in part 
from CDK8-mediated transcriptional reprogramming. 
CDK8 (and its paralog CDK19) can be stimulated by 
p21Cip1 or other CDK-binding proteins. While p21Cip1 
binds to and blocks several cell cycle progression CDKs, 
it also forms a complex with CDK8 and promotes 
the induction of tumor-promoting cytokines. DNA 
damage induced by different drugs is accompanied by 
CDK8/19 transcriptional activation of genes involved in 
the SASP, including cytokines, angiogenic factors and 
mitogens, which ultimately protect tumor cells from 
chemotherapeutic death [26]. High throughput screening 
for candidate compounds downstream of DNA damage-
induced p21Cip1, followed by chemical lead optimization, 
identified Senexin A (and the more potent second 
generation Senexin B) that selectively binds to and blocks 
the ATP pocket of CDK8/19. In vitro, Senexin inhibits the 
secretion of anti-apoptotic factors by doxorubicin-treated 
or γ-irradiated cells, and also blocks the induction of 
cytokines downstream of the TNFα-NFκB axis. Equally as 
significant, Senexin interferes with Wnt3a/β-catenin and 
TGFβ axes-mediated transcription of invasion/migration 
genes. The in vivo effects of Senexin are as promising, 
where treatment of xenograft mouse models inhibits the 
growth of breast and prostate cancers, and markedly 
suppress colon cancers metastasis. The beneficial effects 
of Senexin are further enhanced by preventing CDK8-
mediated activation of STAT1 and its downstream 
suppressive effects on NK cell immune surveillance 
functions. These findings support the development of 
drugs such as CDK8/19 inhibitors, which attenuate the 
senescence-associated tumor-promoting properties of 
chemotherapy. 
Ashani Weeraratna (The Wistar Institute; 
Philadelphia, USA) also argued that senescence is not 
necessarily a good therapeutic endpoint for a couple of 
reasons. First, universal markers of senescence have 
not yet been identified. This makes it difficult to discern 
true senescence from pseudo-senescence that may arise 
from and respond differently to cancer therapy and 
contribute to tumor heterogeneity. Second, senescent 
cells may (and often do) secrete factors that promote 
invasion of surrounding cells and contribute to a pro-
metastatic microenvironment that exacerbates with age. 
In melanoma, cells appear senescent after exposure to 
stressors such as irradiation (IR) or drug therapy [27]. 
These pseudo-senescent cells are growth arrested, express 
classical senescent markers such as SAβG, PML bodies, 
and heterochromatin foci, yet, they are termed pseudo-
senescent because they are resistant to therapy and 
acquire a highly invasive and pro-metastatic phenotype. 
Mechanistically, non-canonical Wnt5a appears to drive 
pseudo-senescence. Compared to low Wnt5a expressing 
melanoma cells, high Wnt5a expressing cells appeared to 
senesce in response to a variety of therapeutically-relevant 
stressors (IR, B-Raf inhibitors) and subsequently acquired 
both invasive and metastatic potential. Conversely, knock-
down of Wnt5a in high expressors blocks senescence and 
metastasis, suggesting that Wnt5a is a critical regulator 
of pseudo-senescence [27]. Dr. Weeraratna further argued 
that senescence, within the context of aging and the aged 
microenvironment, also contributes to more aggressive 
tumors. In vitro, melanoma cells embedded in skin 
equivalents reconstituted with aged (55-65 year-olds) 
patient-derived dermal fibroblasts are significantly more 
invasive than organotypic cultures embedded with young 
(25-35 year-olds) dermal fibroblasts. Similarly, the aged 
microenvironment of C57BL/6 mice promotes melanoma 
progression to metastasis and resistance to chemotherapy. 
Tail vein injection of YUMM1.7 (BrafV600E/Cdkn2a-/-/Pten-
/-) mouse melanoma cells into young (8 weeks) or aged 
(52 weeks) mice, resulted in smaller but substantially 
more aggressive and metastatic tumors in the aged mice, 
which is likely mediated by secreted proteins in the aged 
microenvironment [28]. Secretome analysis identified 
Secreted Frizzled Related Protein (SFRP2) – an inhibitor 
of canonical Wnt-β-Catenin signaling – as a pro-invasive 
and angiogenic factor in melanoma. Moreover, SFRP2 
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protein levels increase with age; and induction of SFRP2 
(and loss of β-Catenin) in aged skin further exacerbated 
the tumor-permissive and therapy-resistant qualities of the 
aged microenvironment by enhancing DNA damage and 
oxidative stress through the inhibition of the redox effector 
APE1 and microphthalmia associated transcription factor 
[28]. Together, these findings suggest a role for senescence 
in creating an aggressive tumor microenvironment in aged 
skin, warranting the development of therapeutics aimed at 
eliminating the detrimental effects of senescent cells.
Lynne Elmore (Virginia Commonwealth 
University; Richmond, USA) emphasized the clinical 
importance of better understanding the relationship 
between therapy-induced senescence and cancer 
recurrence; and whether therapy-induced senescence 
in cancer cells is reversible. This is in spite of the fact 
that lineage-tracing technologies have been lacking in 
the field, which makes single cell fate determination a 
challenge. To this end, the David Gewirtz laboratory (in 
collaboration with Dr. Elmore’s team) then developed a 
single cell approach utilizing flow cytometry to enrich for 
and monitor individual senescent cancer cells over time 
using C12FDG, a fluorescent method to detect SAβG. 
After exposure of cancer cell lines to the chemotherapeutic 
agent etoposide, cells that were concluded to be senescent 
(based on growth arrest and SAβG positivity status) 
were sorted and analyzed for re-entry into a proliferative 
state. Over a period of days (between 10-20 days post-
treatment), individual senescent cancer cells lost SAβG 
positivity and resumed proliferation, suggesting that these 
cells recovered from etoposide-induced senescence – a 
condition that may ultimately facilitate cancer recurrence. 
Verifying whether and how senescence in cancer cells is 
reversible, both in cell culture and in vivo, will help design 
strategies to eliminate cancer relapse in patients who 
have previously been treated with senescence inducing 
chemotherapeutic drugs. Dr. Elmore concluded by 
touching upon her interest in identifying the mechanistic 
role of different SASP factors and microRNAs in 
regulating senescence reversal in cancer cells, as these 
may be novel therapeutic targets to prevent cancer 
recurrence.
FROM CELLULAR SENESCENCE TO 
CANCER IN VIVO
Senescence is an effective barrier to cancer 
progression as it limits the proliferation potential 
of damaged cells. What is less understood is why a 
damaged cell enters senescence rather than apoptosis. 
From a cancer perspective, apoptosis would seem to be 
more advantageous, because it prevents tumorigenesis 
without inflammation – yet senescence is a common 
consequence of oncogenic insults. Understanding why 
senescence occurs could lead to deeper mechanistic 
insights into its role in cancer. The inherent complexities 
associated with cell autonomous and non-autonomous 
effects of senescence and the SASP has made it essential 
to develop more sophisticated in vivo systems in order 
to comprehensively study its multifaceted biological 
significance. 
Gregory David (New York University School 
of Medicine; New York, USA) began this session by 
emphasizing that the contributions of senescent cells 
and the SASP-related inflammatory response to cancer 
progression is context-dependent. Dr. David’s research 
team focuses on Sin3B, a component of the Sin3-HDAC 
co-repressor complex that they found is required for stress-
related senescence induced by either gain of oncogenic 
KRAS or loss of PTEN in prostate and pancreatic cancer 
models, respectively [29]. On the one hand, senescent 
cells that emerge due to oncogenic stress in prostate 
cancer platforms appear to function in a tumor-suppressive 
manner. Compound prostate-specific PTEN-/-Sin3B-/- 
mice, for instance, are blocked from developing and 
accumulating senescent cells and have increased tumor-
associated morbidity and mortality relative to PTEN-/- 
mice. On the other hand – and in stark contrast – pancreas-
specific (and senescence deficient) KRASG12DSin3B-/- mice 
have appreciably delayed conversions of pancreatic 
intraepithelial neoplasia to ductal carcinoma (PDAC) and 
PDAC-associated death [30]. Significantly, the SASP is 
also reduced, along with a reduction in immune infiltrates 
and inflammation. Specifically, deletion of Sin3B results 
in downregulation of key pro-inflammatory cytokines, 
including IL1α and its downstream targets IL6 and 
IL8. Moreover, depletion of IL1α in KRASG12D mice 
phenocopies the tumor-protective effects observed with the 
loss of Sin3B. This demonstrates that the Sin3B-SASP-
IL1α axis is critical for pancreatic cancer progression. 
Interestingly, knockdown of IL1R leads to downregulation 
of the SASP, yet IL1α depletion does not affect the 
induction of senescence per se (as determined by multiple 
markers, including heterochromatin foci formation). Dr. 
David concluded by indicating that delineating the fate 
and context-dependent effects of senescent cells during 
cancer progression will require lineage-tracing platforms 
currently unavailable to the community at large.
Vera Gorbunova (University of Rochester; 
Rochester, USA) has recently embarked on studying 
the effects of senescence in the long-lived and tumor-
resistant naked mole rat (NMR). Similar to mice (but 
unlike humans), NMR somatic cells express telomerase, 
albeit at lower levels, and are not amenable to telomere-
dependent replicative senescence. Nevertheless, they do 
undergo developmental senescence and respond mildly 
to UV- and IR-induced senescence. It remains unclear 
whether this inherent resistance to senescence plays a 
role in extending the lifespan of NMRs – or whether it 
helps protect against senescence-driven tumors, as others 
have argued. Significant findings by the Gorbunova lab 
may help clarify the biological significance of NMR’s 
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inherent resistance to senescence. First, Dr. Gorbunova 
found that, unlike most mammals, the NMR INK4 locus 
codes for pALTInk4a/b, a potent cyclin-dependent kinase 
inhibitor (CDKi) [31]. pALTInk4a/b is an alternatively 
spliced hybrid of p15Ink4b-p16Ink4a comprised of exon 
1 of p15Ink4b and exons 2 and 3 of p16Ink4a. Like its 
counterparts within the INK4 locus (p15Ink4b, p16Ink4a, and 
p19Arf), pALTInk4a/b is induced by contact inhibition and/
or genotoxic stresses. Second, NMRs synthesize high 
molecular mass hyaluronan (HA) which, unlike the five 
times smaller low molecular mass HA expressed by mouse 
and humans, makes dermal fibroblasts hypersensitive 
to contact inhibition. Mechanistically, high molecular 
mass HA signals the expression of pALTInk4a/b through 
CD44. Production of high molecular mass HA by NMRs 
confers cancer resistance and restricts proliferation [32]. 
NMR cells are normally resistant to SV40 LT + HRasV12 
transformation, but shRNA knockdown of HA Synthase 
(HAS2) in NMR dermal fibroblasts co-transfected with 
LT and Ras are prone to growth in soft agar and tumor 
development in xenograft mouse models. NMR-HAS2 
transgenic mice have been developed recently and will be 
instrumental in determining how HA may impact aging, 
senescence, cancer and lifespan.
Norman Sharpless (University of North Carolina 
School of Medicine; Chapel Hill, USA) discussed ways 
his team has used p16Ink4a as a biomarker to measure the 
“molecular/physiologic age” of animal models and people, 
which is a different measure than chronological age. In 
humans, the INK4/ARF locus is strongly associated with 
a variety of age-related diseases, including myocardial 
infarction, stroke, diabetes, glaucoma, aneurysms, and 
cancers. Unlike other CDK inhibitor proteins such as 
p21Cip1 and p27Kip1, the expression of p16Ink4a and p19Arf 
increases with age in both mice and people. Conversely, 
age-prolonging caloric restriction limits increases in 
p16Ink4a levels. Dr. Sharpless argues that the expression 
of p16Ink4a strongly correlates with the overall burden of 
senescent cells and serves as a biomarker of physiologic 
age. For instance, serial measurements of p16Ink4a levels 
in a p16Ink4a-luciferase knock-in mouse model developed 
in his lab shows that p16Ink4a levels increase exponentially 
with age. Parallel measurements of p16Ink4a in humans 
with a recently developed peripheral blood-based CD3+ 
T-cell assay show that on average, p16Ink4a mRNA levels 
increased approximately 1.5 fold per decade of life – an 
increase that begins well in advance of the manifestation 
of “aging phenotypes”. This ultimately results in a 20-fold 
increase in senescence positivity over an eight-decade 
adult lifespan. To what extent the accumulation of p16Ink4a-
positive senescent cells is a result of age-related decline 
in immune surveillance and/or of SASP-related bystander 
effects remains unclear, but mathematical models of the 
observed exponential growth fits well with senescent 
cells promoting the accumulation of more senescent cells. 
Various extrinsic factors were also tested for their effect 
on p16Ink4a induction, including cigarette smoke, exercise 
and chemotherapeutic agents. The number of pack-years 
of smoking correlates with increases in p16Ink4a, while the 
length of exercise sessions inversely correlates with p16 
status. Within the clinical realm, adjuvant chemotherapy 
of breast cancer patients with adriamycin and cytoxan 
is shown to accelerate p16In4a-based molecular aging. In 
turn, there is also preliminary evidence that the p16Ink4a 
pre-treatment status in patients can be predictive of degree 
of chemotherapy toxicity – i.e., the higher the baseline, the 
higher the toxicity. Dr. Sharpless believes that utilization 
of a diagnostic test to measure the amount of p16Ink4a in 
peripheral blood lymphocytes, which is commercially 
available, may provide insight into the “molecular age” 
of patients to provide guidance for therapeutic decisions.
TUMOR IMMUNOLOGY AND 
SENESCENCE
The last session focused on how immune cell 
function may interact with senescent cells to contribute 
to tumorigenesis. This session further highlighted the 
importance of having robust in vivo platforms in which 
to study the interplay between senescence, SASP and 
immune surveillance programs within the context of 
the aging and/or tumor microenvironment. Many of 
these mechanisms are beginning to emerge, and a better 
understanding of how senescent cells are detected 
and selectively eliminated before they disrupt normal 
tissue functions will have wide-ranging translational 
ramifications. 
Lars Zender (University Hospital Tübigen; 
Tübigen, Germany) discussed the complex interplay 
between oncogene-induced senescence and immune 
surveillance in liver tumorigenesis and progression. 
Published work from his lab shows that in vivo liver 
tumor regression mediated by WT-p53 re-activation 
in HRasG12V p53-/- hepatocytes involves the induction 
of senescence, SASP and immune cell recruitment 
into the tumor microenvironment – not apoptosis [33]. 
Consistent with these findings, senescence-induced 
immune surveillance is also relevant to the elimination 
of pre-malignant NRasG12V lesions [34]. Mechanistically, 
rampant senescence and resulting SASP stimulate the 
clearance of senescent cells by attracting CD4+ T-cells 
and CCR2+ inflammatory monocytes. Likewise, NK 
cells also contribute to this coordinated clearance, as 
loss of NK cells accelerates tumorigenesis [33, 34]. 
Furthermore, antibody-mediated depletion of immune 
cells compromises the SASP-activated surveillance, and 
enable hepatocellular carcinomas (HCC) to develop and 
progress unhindered. More recently, secretome analysis 
of the SASP revealed that senescent pre-malignant 
hepatocytes express very high levels of MCP1 (CCL2). 
Mice deficient for the CCL2 receptor (CCR2, expressed 
in inflammatory monocytes, hematopoietic stem cells 
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and subsets of NK cells) have impaired infiltration and 
maturation of bone marrow-derived immature myeloid 
cells (iMC) into macrophages in the senescence-rich liver. 
This in turn impairs the coordinated clearance of pre-
cancerous senescent hepatocytes by the macrophages and 
CD4+ T-cells. The accumulation of iMC in the liver has 
the added negative effect of blocking NK cell function – 
which further compromises the senescence surveillance 
program. Without appropriate immune clearance, NRasG12V 
cells may stochastically bypass senescence, become 
fully tumorigenic, and further fuel iMC maturation/
functional blockade via poorly understood tumor-
secreted factors. In line with this observation, peritumoral 
senescence in both mice and humans track with poor 
HCC prognosis and survival, and support the notion that 
retention/accumulation of senescent cells exacerbate 
the tumor phenotype and is deleterious long-term [35]. 
Basic mechanistic studies as the ones uncovered in the 
Zender lab may help better understand the ramifications 
of targeted therapies for a wide range of senescence-
associated diseases. CCR2 inhibitors, for instance, have 
recently entered clinical trials for patients with diabetic 
nephropathy and Type 2 diabetes. Sadly, liver damage 
(often observed as a precursor to cancer) has been reported 
for these patients, and the extent to which it is linked to 
blocked senescence surveillance remains to be seen.
Daohong Zhou (University of Arkansas; Little 
Rock, USA) discussed how cancer therapies, including 
chemotherapy and ionizing radiation (IR), often induce 
cellular senescence. The induction of senescence in 
response to these signals is beneficial in the short term, 
as it limits the proliferation of damaged cells. However, 
these cells are becoming increasingly recognized as 
deleterious in the long term, as a growing body of 
evidence suggests that the accumulation of senescent 
cells contributes to tissue damage and facilitates tumor 
recurrence and metastases. Dr. Zhou has been focused on 
discovering pharmacological interventions that can target 
senescent cells, so called “senolytic” agents, to selectively 
eliminate them to improve health and the efficacy of 
cancer treatments. One such drug, ABT-263 (Navitoclax), 
a specific Bcl-2 and Bcl-xl inhibitor, is broadly senolytic 
in multiple cell types induced to senesce in several ways 
[36]. Cell death upon ABT-263 treatment is dependent 
on activation of caspases. Administration of ABT-263 
to both aged and sublethally irradiated mice depleted 
senescent hematopoietic stem cells (HSCs) and satellite 
(skeletal muscle stem) cells (MuSCs), which resulted 
in mitigation of myeloid skewing bias from HSCs and 
improved clonogenicity of MuSCs. Dr. Zhou pointed out 
that ABT-263 is not a “fountain of youth”, as this drug has 
significant toxicity and lacks the ability to kill all senescent 
cells. However, preliminary studies suggested that survival 
may be extended with ABT-263 treatment. It will be 
interesting to see how pharmacological interventions 
targeting senescent cells, including ABT-263 and other 
senolytic drugs, impact life and healthspan. 
WORKSHOP SUMMARY
At the conclusion of the workshop, a round table 
discussion led by Judy Campisi (Buck Institute) and Jan 
van Deursen (Mayo Clinic) focused on defining the major 
challenges and opportunities in this emerging research 
area. It was noted how far the field has come in the 
past two decades, during which senescence was viewed 
as a tissue culture “phenomenon” that had little role in 
physiology. The discussion focused on resources, tools and 
technologies, knowledge gaps, and research community 
efforts that will be required to accelerate discoveries. Key 
points are summarized below.
How to properly define senescence
• The term senescence is used to define a cellular 
phenotype that has arisen through various 
means, including developmental cues, tissue 
damage and the stresses of aging. Often the 
underlying reason for a cell becoming senescent 
is unknown or unclear, yet the outcomes are 
grouped into one category. In publications, 
these caveats are not stated, although they may 
impact the conclusions. 
• Should the field establish criteria for concluding 
that a cell is senescent? Or is it favorable to 
have a malleable definition of senescence? 
There was no agreement about whether there 
should be a minimal, rigid criterion or whether 
a more fluid definition is preferred.
Overcoming knowledge gaps
• Senescence in culture can be a highly dynamic 
process as exemplified in what many refer to 
as “deep-senescence”. Is this process also 
dynamic in vivo and what methods are needed 
to test the idea that senescence evolves over 
time in an organism? In addition, there are 
no experimental designs that allows one to 
conclusively demonstrate that senescence 
bypassing promotes intrinsic transformation 
of permanently arrested cells in vivo. Efforts 
should be made to define what “bypassing 
senescence” actually entails from a molecular 
standpoint. To state the problem more simply, is 
senescence actually reversible and is it possible 
for all forms of senescence?
• The contribution of senescent cells to tissue 
and organ phenotypes in vivo is beginning to 
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be elucidated, but it is unclear whether and 
how metabolic alterations influence senescent 
phenotypes and the SASP. We also do not know 
how many senescent cells accumulate with age 
in each tissue, nor how they promote cancer.
• Furthermore, defining the cell autonomous 
effects of the senescence response versus the 
impact on the tissue microenvironment needs 
careful examination.
• Senescence can be beneficial or detrimental, 
depending on the context. Establishing how 
senescent cells contribute to degenerative 
diseases or cancer may be necessary to 
determine whether removal or ablation 
strategies should be utilized. In certain 
cancers, senescent cells may actively promote 
tumorigenesis and resistance to therapy. These 
would be the types of tumors to first test 
whether senolytic interventions are beneficial.
Tool and resource development
•    Clearly the field needs more advanced tools, 
although it is unclear what this tool kit would 
look like. One important tool that needs 
development is the ability to follow and lineage 
trace senescent cells over time in vivo, which 
would help our understanding of their etiology 
and whether (and to what extent) the senescent 
state is reversible. In addition, improved 
animal models are needed to better understand 
the contribution of senescent cells to cancer, 
including the development of mouse models 
that allow for the isolation of senescent cells 
from tissues. 
• More sophisticated tissue culture models 
are also needed not only to determine how 
oncogenic senescence arises, but also to 
identify and characterize the corresponding 
SASP elements/signatures. A variety of cell 
types should be used to determine a “core” 
group of SASP factors that might be universal.
• The field should work to establish a common 
platform for defining the SASP and senescent 
states, both in culture and in vivo. This task may 
require single cell RNA analyses, which would 
be greatly facilitated by the development of 
robotics to perform these analyses. Using these 
tools, one would be able to build signatures of 
the SASP in different senescent states and cell 
types.
Comparative studies
• Studies performed in culture and in lower 
organisms will inform our understanding of 
oncogenic senescence in humans. Uniting 
the basic and clinical sciences is a major 
challenge to this field, but clearly is required 
to translate the conclusions gained from model 
systems into therapeutic opportunities in 
patients. Efforts to support these interactions 
should be encouraged. It is possible that 
clinical applications can be developed despite 
uncertainties about how senescent cells drive 
disease.
Team building
• Rapid progress in the field will require 
the efforts of collaborative teams, ranging 
from basic scientists to clinicians, with 
complementary skillsets and model systems. 
Addressing these critically important needs will 
facilitate scientifically rigorous experimentation 
to fully explore this emerging research area and 
elucidate the relationship between senescence 
and carcinogenesis.
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